Floatz logo

Recombinant Fowlpox-CEA(6D)

Metastases, Neoplasm

National Cancer Institute (NCI)Phase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

171 Active assets in the Metastases, Neoplasm cohort.

Asset / SponsorPhaseRating
Eloxatin
Ruijin Hospital
Phase 4BBB
FLUOROURACILUM
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
DEXAMETHASONE
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 50 →

Same molecule, other indications

Recombinant Fowlpox-CEA(6D) is also rated in:

breast cancerDormant
CC
Indicative ·
47 / 100
View asset →
Adult Solid NeoplasmDormant
CC
Indicative ·
44 / 100
View asset →
colon adenocarcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →